BridgeBio Pharma, Inc. (BBIO)
Market Cap | 4.66B |
Revenue (ttm) | 218.60M |
Net Income (ttm) | -538.26M |
Shares Out | 187.13M |
EPS (ttm) | -3.22 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,472,839 |
Open | 25.20 |
Previous Close | 25.20 |
Day's Range | 24.90 - 25.71 |
52-Week Range | 16.61 - 44.32 |
Beta | 1.08 |
Analysts | Strong Buy |
Price Target | 46.83 (+88.0%) |
Earnings Date | Aug 1, 2024 |
About BBIO
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded... [Read more]
Financial Performance
In 2023, BBIO's revenue was $9.30 million, a decrease of -88.02% compared to the previous year's $77.65 million. Losses were -$643.20 million, 33.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price forecast is $46.83, which is an increase of 88.00% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/k/z/press15-2506903.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised...
![](https://cdn.snapi.dev/images/v1/q/v/press4-2503680.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are a...
![](https://cdn.snapi.dev/images/v1/l/q/press6-2494081.jpg)
Levi & Korsinsky Reminds BridgeBio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/6/q/press3-2494078.jpg)
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/t/w/press1-2492461.jpg)
Lost Money on BridgeBio Pharma, Inc.(BBIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/e/a/press14-2491631.jpg)
BridgeBio Pharma, Inc. (BBIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/k/7/press1-2491638.jpg)
BridgeBio Pharma, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BBIO
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/a/f/press1-2488510.jpg)
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- BBIO
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/s/c/press4-2488411.jpg)
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDA...
![](https://cdn.snapi.dev/images/v1/q/g/press16-2487698.jpg)
ATTENTION BridgeBio Pharma, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/m/0/press18-2485570.jpg)
Lost Money on BridgeBio Pharma, Inc. (BBIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violati...
![](https://cdn.snapi.dev/images/v1/q/d/press2-2484083.jpg)
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected...
![](https://cdn.snapi.dev/images/v1/h/z/press11-2478630.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are a...
![](https://cdn.snapi.dev/images/v1/x/e/press15-2470765.jpg)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
![](https://cdn.snapi.dev/images/v1/w/r/conf17-2465760.jpg)
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
![](https://cdn.snapi.dev/images/v1/h/q/press12-2465690.jpg)
BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRASG12C NSCLC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignanci...
![](https://cdn.snapi.dev/images/v1/h/c/press8-2461045.jpg)
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from...
![](https://cdn.snapi.dev/images/v1/k/m/press6-2459973.jpg)
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that m...
![](https://cdn.snapi.dev/images/v1/m/3/press6-2452473.jpg)
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortali...
![](https://cdn.snapi.dev/images/v1/t/3/conf1-2447006.jpg)
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. o...
![](https://cdn.snapi.dev/images/v1/v/h/conf14-2429053.jpg)
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and c...
![](https://cdn.snapi.dev/images/v1/8/y/press2-2426656.jpg)
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (...
![](https://cdn.snapi.dev/images/v1/e/h/press10-2405704.jpg)
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 ...
![](https://cdn.snapi.dev/images/v1/b/v/press7-2360105.jpg)
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
![](https://cdn.snapi.dev/images/v1/n/h/press13-2310095.jpg)
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today a...